Information Provided By: 
Fly News Breaks for April 4, 2016
REGN
Apr 4, 2016 | 07:19 EDT
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $523 from $505, citing increased dupilumab confidence. Last week dupilumab was "substantially" de-risked for the atopic dermatitis indication, the analyst tells investors in a research note, adding that he believes it will also be for other indications as well. Porges says dupilumab's efficacy and safety in Phase 3 reinforce his bullish view for its commercial prospects. The analyst reiterates an Outperform rating on the shares.
News For REGN From the Last 2 Days
